Sandbox:Sahar: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
==Images==


{| class="wikitable"
{| class="wikitable"
!Organ System Involvement
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}}
!Differential Diagnosis
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
!Causes
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
!Clinical Features
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}}
!Laboratory Findings
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
!Gold Standard Test
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
!Therapy
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}}
|-
|-
| rowspan="9" |'''Nephrotic Syndrome and Renal Failure'''
| rowspan="9" |'''Nephrotic Syndrome and Renal Failure'''
|Secondary (AA) Amyloidosis
|'''[[Secondary (AA) Amyloidosis]]'''
|
|
* Chronic inflammatory disorders
* Chronic [[inflammatory disorders]]
* Chronic infections
* Chronic [[infections]]
|
|
* Periorbital edema
* [[Periorbital edema]]
* Lower extremity edema
* [[Lower extremity edema]]
* Signs/symptoms of underlying inflammatory disorder
* [[Signs]]/[[symptoms]] of underlying inflammatory disorder
|
|
* Proteinuria
* Proteinuria
* Elevated level of [[acute phase reactant]] due to underlying inflammatory condition
* Elevated level of [[acute phase reactant]] due to underlying inflammatory condition
|
|
*  
* Biopsy and congo-red staining of the sample
|
|
* Treatment of the undelying [[iflammatory disorder]]
|-
|-
|Primary (AL) Amyloidosis
|'''[[Primary (AL) Amyloidosis]]'''
|
|
* [[Monoclonal]] [[plasma cell]] proliferation
* [[Monoclonal]] [[plasma cell]] proliferation
Line 66: Line 63:
* [[Kidney transplantation]]
* [[Kidney transplantation]]
|-
|-
|[[Diabetic nephropathy|Diabetic Nephropathy]]
|'''[[Diabetic nephropathy|Diabetic Nephropathy]]'''
|
|
* Hyperfiltration
* Hyperfiltration
Line 91: Line 88:
* [[Glycemic]] control
* [[Glycemic]] control
|-
|-
|[[Minimal change disease|Minimal Change Disease]]
|'''[[Minimal change disease|Minimal Change Disease]]'''
|
|
* [[Upper respiratory tract infection]]
* [[Upper respiratory tract infection]]
Line 120: Line 117:
* Salt restriction
* Salt restriction
|-
|-
|[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]]
|'''[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]]'''
|
|
* [[HIV]]
* [[HIV]]
Line 156: Line 153:
* [[Mycophenolate|Mycophenolate motefil]]
* [[Mycophenolate|Mycophenolate motefil]]
|-
|-
|[[Fabry's disease|Fabry's Disease]]
|'''[[Fabry's disease|Fabry's Disease]]'''
|
|
* Deficient alpha galactosidase A
* Deficient alpha galactosidase A
Line 179: Line 176:
* [[Migalastat]]
* [[Migalastat]]
|-
|-
|Light Chain Deposition Disease
|'''Light Chain Deposition Disease'''
|
|
* [[Multiple myeloma]]
* [[Multiple myeloma]]
Line 203: Line 200:
* [[Kidney transplantation|Kidney transplant]]
* [[Kidney transplantation|Kidney transplant]]
|-
|-
|[[Membranous glomerulonephritis|Membranous Glomerulonephritis]]
|'''[[Membranous glomerulonephritis|Membranous Glomerulonephritis]]'''
|
|
* [[Hepatitis B]] and [[Hepatitis C|C]]
* [[Hepatitis B]] and [[Hepatitis C|C]]
Line 244: Line 241:
* [[Rituximab]]
* [[Rituximab]]
|-
|-
|Fibrillary-Immunotactoid Glomerulopathy
|'''Fibrillary-Immunotactoid Glomerulopathy'''
|
|
* [[Idiopathic]]
* [[Idiopathic]]
Line 261: Line 258:
|
|
|-
|-
!Organ System Involvement
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}}
!Differential Diagnosis
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
!Causes
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
!Clinical Features
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}}
!Laboratory Findings
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
!Gold Standard Test
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
!Therapy
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}}
|-
|-
| rowspan="6" |''Polyneuropathy''
| rowspan="6" |'''Polyneuropathy'''
|'''[[POEMS syndrome]] (Demyelinating)'''
|'''[[POEMS syndrome]] (Demyelinating)'''
|
|
Line 424: Line 421:
* [[Rituximab]]
* [[Rituximab]]
|-
|-
|'''Organ System Involvement'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}}
|'''Differential Diagnosis'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
|'''Causes'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}}
|'''Features'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}}
|'''Laboratory Findings'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Laboratory Findings'''}}
|'''Gold Standard Test'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Gold Standard Test'''}}
|'''Therapy'''
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
|-
|-
| rowspan="7" |''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)''
| rowspan="7" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''
|'''[[Malaria]]'''
|'''[[Malaria]]'''
|
|

Revision as of 22:12, 4 November 2019

Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Nephrotic Syndrome and Renal Failure Secondary (AA) Amyloidosis
  • Biopsy and congo-red staining of the sample
Primary (AL) Amyloidosis


Diabetic Nephropathy
Minimal Change Disease
Focal Segmental Glomerulosclerosis
  • Biopsy:
    • Podocyte foot process effacement
    • Capillary lumen abolished by the segmental increase in matrix
Fabry's Disease
  • Deficient alpha galactosidase A
Light Chain Deposition Disease
  • Biopsy:
    • Non-amyloid granules
Membranous Glomerulonephritis
Fibrillary-Immunotactoid Glomerulopathy
  • Biopsy:
    • Polycloncal IgG deposits
    • Infiltration of glomerular structures by amorphous acellular material (nonbranching fibrils 12-24nm in diameter)
    • Ig heavy-chain and one light-chain subclass
Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Polyneuropathy POEMS syndrome (Demyelinating)
Metabolic Syndrome (Axonal pathology)
Vitamin Deficiencies (Axonal Pathology)



Guillain-Barre Syndrome (Demyelinating)
  • Delayed F waves
  • Clinical diagnostic criteria (progressive weakness of more than two limbs, areflexia, and progression for no more than four weeks)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing)


  • EFNS/PNS criteria
  • Koski criteria
Multifocal Motor Neuropathy
  • Progressive, asymmetric, distal and upper limb predominant weakness
  • No significant sensory abnormalities
  • Areflexia
  • Clinical criteria (EFNS/PNS):
    • Slowly progressive or step-wise progressive, focal, asymmetric limb weakness; i.e., motor involvement in the motor nerve distribution of at least two nerves for > 1 month.
    • No objective sensory abnormalities except for minor vibration sense abnormalities in the lower limbs


Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) Malaria
Kala-azar


Infective Hepatitis
Chronic Myelogenous Leukemia (CML)
Lymphoma
Primary (AL) Amyloidosis
  • Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
  • Congo red staining
  • Melphalan-prednisone/dexamethasone
  • Dexamethasone plus Cyclophosphamide-thalidomide
  • Stem cell transplantation
Gaucher's Disease



Example #1

The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.